A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01478685
Recruitment Status : Completed
First Posted : November 23, 2011
Last Update Posted : March 25, 2016
Information provided by (Responsible Party):
Celgene Corporation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : November 2015
  Study Completion Date : November 2015